The U.S. FDA approved Eli Lilly’s once-daily oral GLP-1 receptor agonist orforglipron, branded Foundayo, for adults with obesity or overweight with weight-related comorbidities. The approval follows Novo Nordisk’s oral Wegovy launch and sets up a rapid head-to-head battle across prescriber adoption, access models and patient uptake. Foundayo’s approval arrives via a speedy review pathway under the FDA’s National Priority Review (CNPV) pilot program and is expected to support broader convenience-driven uptake compared with injectable therapies. Analysts and company commentary point to both dosing convenience and insurer access as defining factors for market share in the oral obesity category. Novo Nordisk moved quickly to defend oral Wegovy’s performance characteristics, including pointing to differences in weight-loss outcomes versus Foundayo and plans to present additional analysis. With no head-to-head trial data reported in the coverage, both companies are leaning on available trial data and simulated comparisons to shape the narrative. The next phase for the category will likely hinge on real-world payer coverage decisions, telehealth distribution dynamics, and whether head-to-head evidence emerges to settle comparative claims.